OUR PARTNERS
We are actively developing alliances with companies, clinicians, patient organizations and academic scientists. Collaborations are core to expand and grow our capabilities, so that we can provide better healthcare for patients.
For more information or inquiries on collaborations and partnerships, please email partner@hengruitherapeutics.com
We are actively developing alliances with companies, clinicians, patient organizations and academic scientists. Collaborations are core to expand and grow our capabilities, so that we can provide better healthcare for patients.
For more information or inquiries on collaborations and partnerships, please email partner@hengruitherapeutics.com
GLOBAL DEVELOPMENT PARTNERSHIPS
In January 2018, TG Therapeutics and Jiangsu Hengrui Medicine announced a global license agreement for development and commercialization of novel BTK Inhibitor Program for the treatment of hematologic malignancies.
|
In January 2018, Arcutis and Jiangsu Hengrui Medicine announced a development and commercialization partnership for novel immune-mediated dermatology therapy using a potentially best-in-class JAK inhibitor discovered by Hengrui.
|
